News &amp; Updates

An updated analysis of MARIPOSA reveals significant reductions in the incidence of MET and EGFR resistance alterations with first-line amivantamab plus lazertinib compared with osimertinib, with no upregulation in other resistance pathways, in patients with nonsmall cell lung cancer (NSCLC).

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

05 Nov 2025

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

Treatment with tislelizumab results in longer overall survival (OS), prolonged progression-free survival (PFS), higher objective response rates (ORRs), more durable responses, and fewer grade ≥3 treatment-emergent (TEAEs) and treatment-related adverse events (TRAEs) compared with docetaxel, according to the RATIONALE-303 study.

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

Endometriosis risk reduced with modest intake of soy products

New research suggests that incorporating even modest amounts of soy into the diet may provide a protective benefit against endometriosis in women.

Endometriosis risk reduced with modest intake of soy products

World’s first RCT on lipofilling in breast-conserving surgery shows promising preliminary results

The world’s first randomized controlled trial (RCT) of lipofilling for immediate breast reconstruction in breast-conserving surgery (BCS), conducted by researchers from the University of Hong Kong (HKU), has shown promising preliminary results and continues to recruit patients.

World’s first RCT on lipofilling in breast-conserving surgery shows promising preliminary results

Intra-arterial alteplase increases likelihood of excellent post-thrombectomy functional outcome

Intra-arterial alteplase (IAA) resulted in a higher likelihood of excellent functional outcome at 90 days among patients with acute, anterior-circulation, large-vessel occlusion (LVO) stroke who achieved successful endovascular reperfusion by mechanical thrombectomy, a study in China has found.

Intra-arterial alteplase increases likelihood of excellent post-thrombectomy functional outcome

Gene variant in Chinese linked to higher Alzheimer’s risk and more severe pathology

The TREM2 H157Y variant gene significantly increases the risk of Alzheimer’s disease (AD) in ethnic Chinese and is associated with more rapid clinical progression and more severe neurodegeneration, researchers from the Hong Kong University of Science and Technology (HKUST) have found.

Gene variant in Chinese linked to higher Alzheimer’s risk and more severe pathology

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

04 Nov 2025 by

Neoadjuvant treatment with tiragolumab plus atezolizumab, with or without chemotherapy, is feasible in advanced resectable non-small cell lung cancer (NSCLC), having an acceptable safety profile and yielding major pathologic response (MPR) rates comparable to that observed with other perioperative immunotherapy plus chemotherapy regimens, according to the phase II SKYSCRAPER-05 trial.

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

Some patients with nonsmall-cell lung cancer (NSCLC) have somatic DNA methyltransferase 3A (DNMT3A) mutations, which are associated with a reduced DNMT3A expression and a favourable immunophenotype, reveals a study.

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

SGLT-2i lowers autoimmune rheumatic disease risk in T2D

04 Nov 2025 by

The use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, results in a reduced risk of autoimmune rheumatic disease among adults with type 2 diabetes (T2D), reports a recent study.

SGLT-2i lowers autoimmune rheumatic disease risk in T2D

04 Nov 2025

Which exercise works best for people with knee OA?

04 Nov 2025 by

Aerobic exercise appears to be the best form of workout for people with knee osteoarthritis (OA), resulting in improved pain, function, gait performance, and quality of life (QoL), suggests a study.

Which exercise works best for people with knee OA?